Head-To-Head Comparison: Aligos Therapeutics (NASDAQ:ALGS) vs. WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares WAVE Life Sciences and Aligos Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
WAVE Life Sciences $42.73 million 11.82 -$204.38 million ($1.07) -2.39
Aligos Therapeutics $2.19 million 3.48 -$24.19 million ($6.35) -0.19

Aligos Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares WAVE Life Sciences and Aligos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WAVE Life Sciences -296.86% -44.66% -36.80%
Aligos Therapeutics -197.01% -206.30% -99.45%

Institutional and Insider Ownership

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

WAVE Life Sciences has a beta of -1.4, meaning that its share price is 240% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for WAVE Life Sciences and Aligos Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences 1 2 15 2 2.90
Aligos Therapeutics 1 0 5 1 2.86

WAVE Life Sciences currently has a consensus price target of $20.44, suggesting a potential upside of 698.61%. Aligos Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 3,055.74%. Given Aligos Therapeutics’ higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than WAVE Life Sciences.

Summary

WAVE Life Sciences beats Aligos Therapeutics on 10 of the 14 factors compared between the two stocks.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.